• U.S. Burden of Skin and Subcutaneous Diseases Increasing

    Healthday News Conditions, HealthDay News Physician's Briefing June 25, 2020
  • Can dermatology employers require employees to receive the COVID-19 vaccine?

    American Academy of Dermatology AAD, Conditions, Coronavirus, COVID-19 January 28, 2021
  • THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS

    American Academy of Dermatology AAD, Atopic Dermatitis, Conditions, Dermatology January 26, 2021
  • Expression of retinoid receptors in hand eczema.

    ClinOwl Atopic Dermatitis, ClinOwl, Conditions, Eczema October 1, 2020
  • S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants

    Healthday News Atopic Dermatitis, Conditions, Eczema July 28, 2020
  • Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.

    ClinOwl ClinOwl, Conditions, COVID-19, Psoriasis July 26, 2020

DermConnect® is an official licensee of the American Academy of Dermatology.

DermConnect®
Navigation
  • Home
  • Atopic Dermatitis
  • Psoriasis
    • Chronic Plaque Psoriasis
    • Guttate Psoriasis
  • Skin Cancer
    • Basal Cell Carcinoma
    • Cutaneous T-cell Lymphoma
    • Dermatofibrosarcoma Protuberans (DFSP)
    • Melanoma
    • Merkel Cell Carcinoma
    • Sebaceous Carcinoma
    • Squamous Cell Carcinoma
  • Home
  • Atopic Dermatitis
  • Psoriasis
    • Chronic Plaque Psoriasis
    • Guttate Psoriasis
  • Skin Cancer
    • Basal Cell Carcinoma
    • Cutaneous T-cell Lymphoma
    • Dermatofibrosarcoma Protuberans (DFSP)
    • Melanoma
    • Merkel Cell Carcinoma
    • Sebaceous Carcinoma
    • Squamous Cell Carcinoma
Home 2020 September

Post Archive by Month

Interventions for chronic palmoplantar pustulosis: abridged Cochrane systematic review and GRADE assessments.

In Dermatology
by ClinOwl
September 21, 2020

Palmoplantar pustulosis (PPP) is a chronic inflammatory disease in which sterile and relapsing pustules appear on the palms and soles.To assess the effects of interventions for chronic PPP to induce …

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).

In Dermatology
by ClinOwl
September 21, 2020

Data for the effect of metabolic syndrome (MetS) on efficacy and safety of biologic agents for psoriasis treatment are limited.To evaluate long-term tildrakizumab efficacy, drug survival, and safety in patients …

View Post

Injuries Associated With Glass Tables Common in U.S.

In HealthDay News
by Healthday
September 21, 2020

56 percent of injuries in National Electronic Injury Surveillance System database due to faulty tables

View Post

Hostility Predicts Mortality in Acute Coronary Syndrome

In HealthDay News
by Healthday
September 21, 2020

More than half of patients scored as hostile; hostility predicts all-cause mortality but not ACS recurrence

View Post

Timing of Gender-Affirming Care Linked to Mental Health

In HealthDay News
by Healthday
September 21, 2020

Mental health worse with late pubertal stage, older age for youth presenting for gender-affirming care

View Post

Impact of Psoriasis Explored for Hospital Outcomes of Acute MI

In HealthDay News
by Healthday
September 21, 2020

Myocardial infarction may occur earlier in life in patients with psoriasis

View Post

Black Women Receive Less Timely Breast Cancer Treatment

In HealthDay News
by Healthday
September 21, 2020

Trend persists regardless of socioeconomic status

View Post

Inverted U-Shaped Link Seen for Sleep Duration, Cognitive Decline

In HealthDay News
by Healthday
September 21, 2020

Decline in global cognitive z-score faster for individuals with ≤4 hours, ≥10 hours of sleep nightly

View Post

Individuals With Autism at Risk for Other Health Conditions

In HealthDay News
by Healthday
September 21, 2020

Risk higher compared with the general population even after controlling for smoking, alcohol use, BMI

View Post

COVID-19 Death Toll Nears 200,000 in the United States

In HealthDay News
by Healthday
September 21, 2020

Conceivable that death toll could reach 300,000 if Americans start to relax social distancing measures

  • Page 13 of 19
  • ←
  • 1
  • ...
  • 12
  • 13
  • 14
  • ...
  • 19
  • →

TRENDING

  • Dose Range for Iberdomide Studied in Systemic Lupus Erythematosus
  • YouTube Video Quality for Aesthetic Injectables Lower Than Quality of Websites
  • Cardiac Biomarkers and CV Risk Examined in Psoriatic Disease
  • Lymph Node Dissection Declining in SLN-Positive Melanoma
  • Debt Valuation of Private Equity-Backed Dermatology Groups Down

About DermConnect®

DermConnect® curates the latest in dermatology news and resources from some of the most trusted and respected names in healthcare, including the American Academy of Dermatology, ClinOwl, HealthDay and Dermnet NZ.

LATEST ARTICLES

  • Dose Range for Iberdomide Studied in Systemic Lupus Erythematosus March 16, 2022
  • YouTube Video Quality for Aesthetic Injectables Lower Than Quality of Websites March 11, 2022
  • Cardiac Biomarkers and CV Risk Examined in Psoriatic Disease March 11, 2022
  • Lymph Node Dissection Declining in SLN-Positive Melanoma March 9, 2022
  • Debt Valuation of Private Equity-Backed Dermatology Groups Down March 9, 2022

Quick Links

  • Home
  • Atopic Dermatitis
  • Psoriasis
    • Chronic Plaque Psoriasis
    • Guttate Psoriasis
  • Skin Cancer
    • Basal Cell Carcinoma
    • Cutaneous T-cell Lymphoma
    • Dermatofibrosarcoma Protuberans (DFSP)
    • Melanoma
    • Merkel Cell Carcinoma
    • Sebaceous Carcinoma
    • Squamous Cell Carcinoma

About DermConnect®

DermConnect® curates the latest in dermatology news and resources from some of the most trusted and respected names in healthcare, including the American Academy of Dermatology, ClinOwl, HealthDay and Dermnet NZ.

SCHEDULE

September 2020
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
« Jul   Oct »

All content indicated on this website as authored by "AAD" is owned by and licensed with the permission of the American Academy of Dermatology (“AAD”) for personal educational use.

The content may not be distributed in whole or in part to any third parties without express written permission from AAD,
nor may viewers of this site translate, edit, modify or otherwise create derivative works from the content.

The licensing of the content by AAD does not constitute or imply any endorsement of any company and/or any of its goods, services or written work product.

 

  • Home
  • Atopic Dermatitis
  • Psoriasis
  • Skin Cancer